Carregant...
Use of a novel cytotoxic HEXIM1 peptide in the directed breast cancer therapy
Hexamethylene bisacetamide-inducible protein 1 (HEXIM1) is best known as the inhibitor of positive transcription elongation factor b (P-TEFb) and is recently identified as a novel positive regulator of p53. We previously showed the basic region (BR) of HEXIM1 mediates the binding of HEXIM1 to a nucl...
Guardat en:
| Publicat a: | Oncotarget |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Impact Journals LLC
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868700/ https://ncbi.nlm.nih.gov/pubmed/26734838 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6794 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|